SCHEMBL13633339

SCHEMBL13633339

CCc1cn2cc(C)ccc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.52
RAB9A P51151 5/20 0.52
KDM4E B2RXH2 4/20 0.52
ALDH1A1 P00352 2/20 0.52
KMT2A Q03164 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
PAX8 Q06710 2/20 0.52
MEN1 O00255 1/20 0.52
MITF O75030 1/20 0.52
KDM5A P29375 1/20 0.52
KDM5C P41229 1/20 0.52
TP53 P04637 2/20 0.47
PKM P14618 2/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
CDK5 Q00535 1/20 0.47
CDK5R1 Q15078 1/20 0.47
HSD17B10 Q99714 1/20 0.47
APP P05067 2/20 0.46
METTL3 Q86U44 10/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13572991 0.85 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL23530863 0.82 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL9570490 0.82 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL8174291 0.82 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL10222603 0.82 KDM4E (0.44) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL870522 0.82 NPC1 (0.50) NPC1RAB9AKDM4EALDH1A1KMT2A
Hydrochloric Acid SCHEMBL22499245 0.81 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1KMT2A
Hydrochloric Acid SCHEMBL22499393 0.81 NPC1 (0.49) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL20713612 0.81 APP (0.46) NPC1RAB9AKDM4EALDH1A1KMT2A
SCHEMBL8180039 0.81 GRM5 (0.47) NPC1RAB9AKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252605-B1 LABELLED ANALOGUES OF HALOBENZAMIDES AS MULTIMODAL RADIOPHARMACEUTICALS AND THEIR PRECURSORS INST NAT SANTE RECH MED (FR) 2018-06-13 EP disclosed
US-7615639-B2 1-pyridyl-benzofuro[3,2-b]pyridin-2(1H)-ones TIBOTEC PHARMACEUTICALS, LTD. (IE) 2009-11-10 US disclosed
US-20070265295-A1 1-Heterocyclyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265295-A1 1-Heterocyclyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones CBR1, HRH4, CYP4B1 NPC1 1013/4885RAB9A 3284/4885KDM4E 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.